Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.
B cells and cancer: To B or not to B?
F. Petitprez’s present address is MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
Disclosures: T.W.-W. Chen reported personal fees from Novartis, Roche, Eli Lilly, Daiichi Sankyio, and Eisai outside the submitted work. No other disclosures were reported.
- Views Icon Views
- Share Icon Share
- Search Site
Wolf Herman Fridman, Florent Petitprez, Maxime Meylan, Tom Wei-Wu Chen, Cheng-Ming Sun, Lubka T. Roumenina, Catherine Sautès-Fridman; B cells and cancer: To B or not to B?. J Exp Med 4 January 2021; 218 (1): e20200851. doi: https://doi.org/10.1084/jem.20200851
Download citation file: